Global advances in integrative medicine and health

Healthcare Providers' Views on Psychedelic Therapies in Medical Care: Offering Assisted Dying but Not Psychedelic Prescriptions

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Healthcare providers' perspectives on psychedelic-assisted therapy (PAT) in Canada are underexplored.

  • Attitudes toward ketamine, psilocybin, and MDMA among healthcare providers may vary significantly.
  • Systemic factors, such as regulatory frameworks, could impact the implementation of psychedelic therapies.
  • Ethical considerations are associated with the acceptance of PAT in palliative and oncology care contexts.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
PubMed

Related papers

Dec '21
Palliative care providers' views on deep emotional suffering and using psychedelics for treatment
top 20% journal
cited by 32 papers
journal article
Sep '25
Patient Views on Using Psychedelic Therapy to Help Cancer-Related Emotional Challenges
top 30% journal
cited by 1 paper
journal article
Jun '26
Early experiences using psilocybin therapy to support cancer patients receiving palliative care
top 30% journal
journal article
Sep '24
Psychedelic-assisted therapy for anxiety, depression, and distress in people with serious illnesses
cited by 25 papers
systematic review
Nov '25
Ethical issues in using therapeutic touch during psychedelic-assisted therapy based on researchers’ views and experiences
top 20% journal
journal article
May '24
Palliative care patients' views and willingness to try psilocybin therapy for end-of-life distress
top 20% journal
cited by 3 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the psychedelic science brief

issue #46
Psilocybin cut two specific brain chemicals in depressed patients — here's what that means
yesterday7 studies
issue #44
Psilocybin rewires brain feedback circuits for weeks after a single dose, new evidence shows
1 week ago7 studies
issue #43
A pill form of ketamine cut dissociation to near-zero vs. nasal spray's 29.6-point spike — but missed its main antidepressant target
2 weeks ago7 studies
issue #42
At-home ketamine injections cut depression scores by more than half in 3,870 patients
3 weeks ago8 studies
issue #41
Psychedelics disrupt brain signal flow in both humans and mice across LSD, psilocybin, and MDMA
4 weeks ago7 studies
issue #40
Inhaled 5-MeO-DMT cut postpartum depression scores by 35 points
5 weeks ago7 studies
issue #39
Psilocybin's antidepressant effects lasted 12 months in 126 treatment-resistant patients
6 weeks ago7 studies
issue #38
Buprenorphine extends ketamine's anti-suicide effects for 4 weeks in depression trial
7 weeks ago7 studies
issue #36
Psilocybin helped 18 out of 20 people stay off cocaine for 6 months
9 weeks ago7 studies
issue #35
Psilocybin reduces specific brain cells' activity while boosting others
10 weeks ago7 studies
explore the archive
See more issues from the psychedelic science brief